Search results

Institutional pharmaceutical services have widely evolved over the past 20‐30 years. Hospital pharmacy practice has changed from a profession concerned chiefly with the bulk preparation and distribution of drug products to one centred on ensuring optimal drug therapy. Whereas hospital pharmacists were charged with maintaining large drug stock on nursing units, many of them now provide individualised patient therapies. The practice of hospital pharmacy has therefore become one encompassing all aspects of drug therapy, from the procurement of drugs and drug delivery devices, their preparation and distribution, to their most appropriate selection and use for each patient. Hospital pharmacy services have traditionally had little involvement at the key stages in patients’ hospital care. This leads to the conclusion that the model of clinical pharmacy practice adopted by many pharmacy department hospitals is no longer appropriate for the demands of today’s health‐care services. Reviews many new models proposed for clinical pharmacy practice including an integrated model for providing a pharmaceutical care management approach in the health‐care system. This model is a response to the failures of traditional drug therapy. It is primarily an idea about how health professionals and patient should integrate their work to obtain outcomes important to patients and clinicians.

The purpose of this paper is to examine the pharmaceutical supply chain for artemisinin‐based combination therapies (ACT) in Ghana.

This study employed an inductive approach in examining the dynamics of the pharmaceutical supply chain. The study also used analytical hierarchical process in identifying factors that are detrimental to the ACT supply chain.

The study revealed that there are basically two main supply channels through which ACT enters the Ghanaian pharmaceutical system – private and public. The ACT network depicts a strong evidence of actor interdependence and long‐term relationships. However, the key supply chain enabler – the use of information technology – was found to be lacking, leading to delays and disruptions in the supply chain system. Disruption was found to be the main detrimental factor to the supply chain although delay was found to be occurring more frequently. Price increases indicated a low effect on the supply network at the pharmacy level, but the general price of the highly subsidised effective ACT (Coartem) remains very high.

Owing to constraints in accessibility, it was challenging to contact all the actors in the network individually, especially the consumer. Drugs considered in the study were the WHO approved ACT, even though efforts were made to compile available anti‐malarial drugs on the market.

This study has provided insights into the supply chain for ACT. The findings of the study are relevant in improving the supply chain system.

The paper brings to the fore the need for a proper pharmaceutical supply chain management in the health sector with regards to one of the world's most infectious and deadly diseases – malaria.

Examines the impact of genetic testing and therapy on health care in light of the development of the system in the USA since the turn of the twentieth century. Genetic testing and therapy have the potential to create a great advance in health care but also to become a business of multi‐billion dollar proportions. If present trends of investment and long‐range plans mature, health care will be adversely affected in terms of its distribution, access and economy. Developed and sold as commodities in a free‐market economy, genetic advances will economically stress health care and fail to meet the ethical and legal standards demanded by voluntary informed consent and counseling. Without abandonment of the marketplace approach to health care and thorough reform, many will find themselves excluded from the benefits and vulnerable to discrimination.

The purpose of this study is to identify medical service quality factors that patients care about and establish a medical service quality evaluation index system by analyzing online reviews of medical and healthcare service platforms in combination with a questionnaire survey.

This study adopts a combination of review mining and questionnaire surveys. The latent Dirichlet allocation (LDA) model was used to mine hospital reviews on the medical and healthcare service platform to obtain the medical service quality factors that patients pay attention to, and then the questionnaire was administered to obtain the relative importance of these factors to patients' perception of service quality. Finally, the index system was established.

The medical service quality factors patients care about include medical skills and ethics, registration service, operation effect, consulting communication, drug therapy, diagnosis process and medical equipment.

The identification of medical service quality factors provides a reference for medical institutions to improve their medical service quality.

This study uses online review mining to obtain medical service quality factors from the perspective of patients, which is different from previous methods of obtaining factors from relevant literature or expert judgments; then, based on the mining results, a medical service quality evaluation index system is established by using questionnaire data.

This study explored health insurance coverage of genetic testing and potential factors associated with precision medicine (PM) reimbursement in Thailand.

The study employed a targeted review method. Thirteen PMs were selected to represent four PM categories: targeted cancer therapy candidate, prediction of adverse drug reactions (ADRs), dose adjustment and cancer risk prediction. Content analysis was performed to compare access to PMs among three health insurance schemes in Thailand. The primary outcome of the study was evaluating PM test reimbursement status. Secondary outcomes included clinical practice guidelines, PMs statement in FDA-approved leaflet and economic evaluation.

Civil Servant Medical Benefits Scheme (CSMBS) provided more generous access to PM than Universal Coverage Scheme (UCS) and Social Security Scheme (SSS). Evidence of economic evaluations likely impacted the reimbursement decisions of SSS and UCS, while the information provided in FDA-approved leaflets seemed to impact the reimbursement decisions of CSMBS. Three health insurance schemes provided adequate access to PM tests for some cancer-targeted therapies, while gaps existed for access to PM tests for serious ADRs prevention, dose adjustment and cancer risk prediction.

This was the first study to explore the situation of access to PMs in Thailand. The evidence alerts public health insurance schemes to reconsider access to PMs. Development of health technology assessment guidelines for PM test reimbursement decisions should be prioritized.

General practitioner prescribing is a subject of legitimate interest to all those concerned with the quality of patient care. The analysis of prescribing and cost data can reveal much about this quality. Suggests that both general practitioners and those who administer and advise on family practitioner services will need to understand the issues involved. Warns that, taken in isolation, prescribing data can be misleading, and it must be compared with other aspects of patient care. Simple calculations can suggest areas of possible under‐prescribing and over‐prescribing, and in turn lead to consideration of the criteria for diagnosis of common chronic diseases such as asthma and diabetes, as well as their subsequent management. Suggests that the prescribing of both new drugs and those of dubious merit is a subject for particular scrutiny, and those who prescribe these drugs must accept the duty of extra vigilance this imposes on them.

The objectives of this paper are to describe the “affordable drugs movement” and present a social marketing framework to place major developments within a meaningful theoretical context.

Specific examples are used to illustrate the framework and its utility in understanding the complexities of the pharmaceutical market. Methods to research the dynamics of the market are also presented.

Provides referenced descriptions and examples of forces causing change within the pharmaceutical market. Classifies forces into six conditions influencing successful social movements: structural conduciveness, structural strains, growth of generalized beliefs, precipitating events, mobilization for action, and utilization of social control by opponents. Suggests social research methodologies to study the conditions in greater depth.

This is a descriptive framework that has not been validated for its use in the pharmaceutical market.

Offers a useful framework for academics, managers, students, and individuals to classify and study developments in the pharmaceutical industry.

This paper provides an overview of major forces within the pharmaceutical market and offers direction for those who wish to explore it in greater detail.

A phobia is a condition that is caused by fear of a specific object or situation. Phobias constitute the most common form of psychiatric disorder. “People of all ages, at all income levels and in all geographic locations suffer from phobias, according to a study of the National Institute of Mental Health (NIMH). Between 5.1 percent and 12.5 percent of Americans suffer from phobias.”

The purpose of this paper is to introduce neurological networks as a new metaphor for industrial networks. It also discusses a dysfunction of neurological networks, called writer's block, and compares the disease and potential cures with parallel issues in business networks. The issues raised should alert managers to the disabling effects of anxiety and stress on the functioning of the neurological network of creative individuals.

The paper is a conceptual contribution based on a literature study and empirical observations by the author.

The paper highlights some parallels between the two different networks, because of their functions as communication and interactive systems. Insights are offered into the way current challenges in networks may be solved strategically. The paper also presents some observations on research in the field of business marketing and business networking in general.

Problems in networks may not be solved by pressing on with existing routines. Managers may better think in terms of cures for structural problems. Also, blockage of a network may occur due to pressures and not due to competence problems. Thus, practitioners may rethink their network strategies.

A new metaphor for business networks is introduced by discussing neurological networks, their potential failure and potential cures. New views on strategy are suggested.